Prime Medicine’s modular editing tech may lower off-target risk, but key data and funding milestones remain ahead. Find out ...

The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid to focus resources on a pair of cancer cell therapies.

In the latest market close, CRISPR Therapeutics AG (CRSP) reached $39.11, with a +1.48% movement compared to the previous day. This move lagged the S&P 500's daily gain of 2.03%. At the same time, the ...

Caribou is enrolling a 20-patient confirmatory cohort using the company's HLA matching strategy in the ANTLER Phase 1 clinical trial in second-line large B cell lymphoma (2L LBCL). In H2 2025, Caribou ...

Caribou Biosciences (CRBU) announced a strategic pipeline prioritization with workforce and cost reduction initiatives to focus resources on ...

Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Plant breeding plays a vital role in ensuring global food security by increasing crop yields, improving nutritional quality ...

The Global Cell And Gene Therapy Market is valued at USD 20.5 Billion in 2024 and is projected to reach a value of USD 128.8 ...

In April 2025, Kamau Therapeutics announced a study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel ...

An expert panel will discuss the latest research on CRISPR and how to use it in biotechnology and disease research.

Genome editing has advanced at a rapid pace with promising results for treating genetic conditions—but there is always room ...